Notice to convene Herantis Pharma Plc's Extraordinary General Meeting of shareholders

Notice to convene Herantis Pharma Plc's Extraordinary General Meeting of shareholders

Herantis Pharma Plc
Company release 15 February 2019 at 9:30 am

NOTICE TO CONVENE HERANTIS PHARMA PLC'S EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

Shareholders of Herantis Pharma Plc are invited to attend an Extraordinary General Meeting of the Company on Tuesday, 12 March 2019, commencing at 13.00 (EET) at Taitotalon Kongressikeskus, at the address of Valimotie 8, Helsinki, Finland. Please note that there are a limited number of parking spaces in the area.

The reception of participants and the distribution of voting tickets will commence, and coffee will be served, at 12.30 pm.

A Matters on the agenda of the Extraordinary General Meeting of Shareholders

At the Extraordinary General Meeting of Shareholders, the following matters will be considered:

1          OPENING OF THE MEETING

2          CALLING THE MEETING TO ORDER

3          ELECTION OF PERSONS TO SCRUTINIZE THE MINUTES AND TO SUPERVISE THE COUNTING OF VOTES

4          RECORDING THE LEGALITY OF THE MEETING

5          RECORDING THE ATTENDANCE AT THE MEETING AND ADOPTION OF THE LIST OF VOTES

6          RESOLUTION ON THE NUMBER OF THE MEMBERS OF THE BOARD OF DIRECTORS

The Board of Directors proposes that the number of members of the Board of Directors is increased from five (5) to six (6).

7          RESOLUTION ON THE ELECTION OF A NEW MEMBER OF THE BOARD OF DIRECTORS

The Board of Directors proposes that, in accordance with her consent, Ingrid Heiman is elected to the Board of Directors as a new member. Ingrid Heiman is deemed to be independent of the Company and independent of any significant shareholders of the Company. Ingrid Heiman's brief biography can be found as an appendix to this notice.

8          AUTHORISATION OF THE BOARD OF DIRECTORS TO DECIDE ON ISSUING SHARES

The Board of Directors proposes that the Extraordinary General Meeting of Shareholders authorise the Board of Directors to decide on the issuance of shares as follows:

The shares issued under the authorisation may be new shares or treasury shares. Under the authorisation, a maximum of 1,500,000 shares, which corresponds to approximately 30.5 percent of all of the shares in the Company, may be issued. The shares may be issued in one or more tranches.